Sentieon company logo

The profile is currenly unclaimed by the seller. All information is provided by CB Insights.

sentieon.com

Stage

Series B | Alive

About Sentieon

Sentieon provides scientists, clinicians, patients and consumers with accurate genomic information for precision medicine. Sentieon's technology brings cycle time, accuracy and precision to the bioinformatics market. Sentieon's product roadmap includes distinguishing malignant tumors from benign tumors for cancer diagnostics and other unsolved problems in the burgeoning genomics industry.

Sentieon Headquarter Location

465 Fairchild Drive Suite 135

Mountain View, California, 94043,

United States

650-282-5650

Predict your next investment

The CB Insights tech market intelligence platform analyzes millions of data points on venture capital, startups, patents , partnerships and news mentions to help you see tomorrow's opportunities, today.

Expert Collections containing Sentieon

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

Sentieon is included in 5 Expert Collections, including Medical Devices.

M

Medical Devices

7,910 items

Companies developing medical devices (per the IMDRF's definition of "medical device"). Includes software, lab-developed tests (LDTs), and combination products. *Columns updated as regularly as possible.

C

Cancer

3,605 items

Companies researching, developing, or offering products & services that aid in the screening, prevention, diagnosis, management, and treatment of cancer.

D

Digital Health

12,788 items

Technologies, platforms, and systems that engage consumers for lifestyle, wellness, or health-related purposes; capture, store, or transmit health data; and/or support life science and clinical operations. (DiME, DTA, HealthXL, & NODE.Health)

O

Omics

1,265 items

Companies involved in the capture, sequencing, and/or analysis of genomic, transcriptomic, proteomic, and/or metabolomic data

H

Health IT

10,130 items

This collection includes public and private companies, as well as startups, that market software solutions to healthcare provider organizations.

Sentieon Patents

Sentieon has filed 2 patents.

patents chart

Application Date

Grant Date

Title

Related Topics

Status

3/24/2016

9/24/2019

Bioinformatics, Molecular biology, Genetics, DNA, Computational phylogenetics

Grant

Application Date

3/24/2016

Grant Date

9/24/2019

Title

Related Topics

Bioinformatics, Molecular biology, Genetics, DNA, Computational phylogenetics

Status

Grant

Latest Sentieon News

Element Biosciences Partners With Informatics Experts Sentieon and Google DeepVariant to Validate the AVITI™ System’s NGS Data Quality for Variant Calling

Feb 28, 2022

February 28, 2022 08:00 AM Eastern Standard Time SAN DIEGO--( BUSINESS WIRE )-- Element Biosciences Inc ., developer of a new and disruptive DNA sequencing platform, today announced partnerships with both Google DeepVariant and Sentieon for variant calling analysis. Through the partnerships, the DeepVariant and Sentieon teams have evaluated Element data and generated Element-specific machine learning models. Element will continue to work with both teams to further improve quality and ease of use. Customers who purchase an Element instrument will be offered a 6-month Sentieon license to process Element data at no cost. The rapid expansion of next-generation sequencing (NGS) data and the use of these data in a wide range of new applications has created a need for improved computational tools for data processing. Google DeepVariant, a deep learning technology, was specifically designed to reconstruct genome sequences from NGS sequencing data with significantly greater accuracy than previous classical methods. DeepVariant accomplishes this by transforming the task of NGS variant calling into an image classification problem well-suited to Google’s existing technology and expertise. DeepVariant is available under the BSD open source license. Sentieon, a developer of highly accurate and optimized algorithms for bioinformatics applications, has created tools that are faster and cheaper alternatives to the industry standard for secondary analysis in NGS data processing. Sentieon technology provides high accuracy and ease of use, while dramatically improving processing speed. “We are excited about the partnerships with both Sentieon and Google DeepVariant, and the high data quality our new AVITI System has demonstrated with both of their variant calling algorithms. This will only further enhance the user experience for all our respective customers,” said Molly He, Ph.D., CEO, and co-founder of Element. “We are delighted to support Element Biosciences’ AVITI sequencing platform as it enters the NGS market,” said Jun Ye, CEO of Sentieon. “This partnership enables Element’s customers to benefit from each of our respective strengths in NGS data generation and data analysis. It has been a pleasure working with Element to improve variant calling. Their data has consistently high quality, leading to very accurate variant calling results. We look forward to serving their customers and continuing our collaborations.” “We are excited to see a new sequencing technology,” said Andrew Carroll, Product Lead – Genomics at Google. “We've observed high data quality with our existing methods, and further improvements with re-trained approaches. We've seen especially good performance at lower coverages, which suggests Element may have some read-level accuracy advantages." Detailed results of the studies with Sentieon and Google will be released March 14, 2022. About Google Google’s mission is to organize the world’s information and make it universally accessible and useful. Through products and platforms like Search, Maps, Gmail, Android, Google Play, Chrome, and YouTube, Google plays a meaningful role in the daily lives of billions of people and has become one of the most widely-known companies in the world. Google is a subsidiary of Alphabet Inc. For more information, visit our Google AI Blog https://ai.googleblog.com/ . About Sentieon Sentieon® develops award winning, extremely accurate and highly-optimized algorithms and software for bioinformatics data processing applications. Sentieon® is a team of professional engineers with deep expertise in algorithm, software, and system optimization acquired through experience developing image processing, computational lithography, large-scale data mining, and bioinformatics applications. Using our accumulated expertise in modeling, optimization, machine learning, and high-performance computing, we strive to enable precision data for precision medicine. For more information, visit www.sentieon.com . About Element Biosciences, Inc. Element Biosciences is a multi-disciplinary life science company currently focused on developing disruptive DNA sequencing technology for research and diagnostic markets. Through innovating every fundamental element of a sequencing system, Element will empower customers with affordable high-quality data and an improved user experience, which in turn will accelerate scientific discoveries and broaden the use of genomic medicine. To learn more about Element, please visit www.elementbiosciences.com . Contacts

Sentieon Web Traffic

Rank
Page Views per User (PVPU)
Page Views per Million (PVPM)
Reach per Million (RPM)
CBI Logo

Sentieon Rank

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.